Research on type 2 diabetes and its management. Covers nerve pain, early onset, BMI trajectories, and treatment side effects.
The Novo Nordisk Foundation has renewed its $53 million commitment to the Broad Institute's Center for Genomic Mechanisms of Disease. This funding will accelerate research into the genetic and biological mechanisms underlying type 2 diabetes and obesity, with the goal of identifying new therapeutic targets. The center will expand on it...
Researchers aim to identify biological mechanisms behind insulin resistance and develop therapeutic strategies. The study focuses on skeletal muscle tissue from lean and obese individuals, exploring protein modifications that distinguish insulin-sensitive from insulin-resistant muscle.
Women are more likely to experience weight loss and improved blood sugar control with GLP-1 RAs, but face higher rates of side effects and unequal access to treatment worldwide. Extensive research is needed to address these disparities and optimize treatment for women in various domains.
Retatrutide demonstrates substantial weight loss and improved blood sugar control in adults with overweight and type 2 diabetes, with 47% of participants losing at least 20% of their starting weight. The treatment also improves cardiometabolic risk factors and reduces inflammation.
A new AI-based tool uses speech analysis to detect type 2 diabetes in just 20 seconds, with high accuracy rates. The model performed well across different sexes and ages, but had lower performance on recordings from Black participants and those with heart disease, high blood pressure, or obesity.
A study of 2 million adults in Ontario, Canada, found that moving from a high-poverty to a lower poverty neighbourhood significantly lowers the risk of developing type 2 diabetes. Individuals who moved experienced a 57% lower risk compared to those who remained in the same high-poverty area.
Researchers have identified a unique 'bacterial signature' that flags individuals at risk of type 2 diabetes, even if their blood sugar levels are normal. The study analyzed data from over 200,000 adults and found that changes in the gut microbiome can be detected before the onset of diabetes.
A new study found that consuming red meat linked to a 63% higher risk of developing type 2 diabetes due to Neu5Gc, a non-human sugar found in red meat. Higher levels of Neu5Gc were associated with greater risk, even after adjusting for other factors.
A study of over 6 million people found that individuals diagnosed with type 2 diabetes before the age of 20 were more likely to have ADHD (14%) and autism (5.7%) compared to those without T2D. This suggests that healthcare systems may need to consider the needs of neurodivergent people when providing care for early-onset T2D.
A new study suggests that eating a diet low in ultra-processed foods and exercising regularly can reduce the risk of type 2 diabetes, even in those with a strong genetic predisposition. The analysis of data on tens of thousands of people found that those who followed these habits were up to 70% less likely to develop the condition.
A new post-hoc analysis of the ATTAIN-1 and -2 studies found significant and similar weight reductions for women of different menopausal status, with up to 14% body weight loss and 12.5cm waist circumference reduction
A study of 1.6 million patients found that the risk of developing chronic kidney disease or heart failure increases substantially over time after a type 2 diabetes diagnosis. Early, proactive management is crucial to reduce the risk of serious complications.
A new study published in JAMA Network Open found that Black and Hispanic patients are less likely to adhere to their diabetes medications compared to White patients. The study, which analyzed national health data from 2019, showed that extra assistance programs significantly reduced treatment gaps, particularly for high-cost treatments.
A nationwide study in Denmark found that cancer incidence is 12% higher among men with type 2 diabetes and 22% higher among women with type 2 diabetes compared to those without diabetes. Obesity-related cancers, such as colorectal and postmenopausal breast cancer, are particularly prevalent among people with type 2 diabetes.
A UK Biobank study found that higher levels of moderate-to-vigorous physical activity are associated with a substantially lower risk of developing type 2 diabetes, particularly among younger adults. Encouraging older adults to be physically active could prevent more cases of type 2 diabetes due to their high overall risk.
The EASD has published its first evidence-based clinical practice guideline on diabetes distress, emphasizing the importance of assessing and managing emotional burdens in adults with type 1 and type 2 diabetes. The guideline aims to improve clinical care and outcomes by incorporating a person-centered approach to diabetes care.
Researchers at Pennington Biomedical developed GVC-Calc to analyze continuous glucose monitoring data, providing a scalable and transparent approach. The platform supports batch processing, integrates individual-level data with cohort-level results, and offers consensus clinical metrics alongside exploratory measures.
Researchers identified a distinct risk profile for young adults with early-onset fatty liver disease, associated with genetic factors and metabolic conditions like type 2 diabetes. The study highlights the need for more accurate liver screening and assessment for individuals at greatest risk.
Researchers at UTHealth Houston developed a treatment that reverses nerve pain in diabetic mice by targeting the MMP-9 enzyme, which breaks down proteins and causes immune response. The new monoclonal antibodies selectively inhibit MMP-9 activity, regenerating nerve fibers and improving wound healing.
Women with a history of gestational diabetes in pregnancy are at a substantially increased risk of developing type 2 diabetes later in life, with a median onset age 13 years earlier than those without prior gestational diabetes. They also experience more severe disease, requiring insulin treatment more frequently.
A recent study identified three distinct BMI trajectories among people with type 2 diabetes, with stable, increasing, and decreasing trajectories associated with different comorbidities and healthcare service use. Increasing BMI was linked to a clustering of chronic diseases, while weight loss was not always indicative of better health...
A study found that SGLT2 inhibitors increase the risk of ketoacidosis in patients with type 2 diabetes who have high blood glucose, low body weight, or a history of ketoacidosis. The risk persists throughout treatment duration, highlighting the need for better support for high-risk patients.
A study published in PLOS Medicine found that women with type 2 diabetes are more likely to develop mental health conditions, while men experience more cardiovascular and renal complications. The researchers analyzed data from 28,720 men and women in the UK, revealing significant sex differences in disease trajectories.
A 10-fold increase in new case rate of type 2 diabetes in young people under 20 years old since the turn of century has led to a significant shift in the disease's demographics. The study found an accelerating trend in type 2 diabetes incidence, with a 3.8% annual increase between 2002 and 2023.
Researchers suggest that targeting tiny protein aggregates known as oligomers, which form early in the disease process, may lead to breakthroughs in treating protein-misfolding diseases. Oligomers are increasingly believed to drive cellular damage, and their early formation may be more toxic than large protein deposits.
A key molecule released during exercise, L-β-aminoisobutyric acid (L-BAIBA), has been discovered to strengthen muscles, improve exercise performance, and protect against muscle damage in type 2 diabetes. The study reveals L-BAIBA's role in muscle adaptation, metabolism, and contraction, offering promising insights for future therapies.
Research shows a link between dollar store food quality and higher rates of obesity, high blood pressure, and type 2 diabetes. Traditional grocery store access is associated with better health metrics, according to a new study published in BMC Public Health.
A new study has found that women with endometriosis are at a 46% higher risk of developing type 2 diabetes. The study analyzed nearly 3 million women over 25 years and suggests that chronic inflammation associated with endometriosis may play a role in metabolic health.
Tirzepatide has been shown to reduce the risk of heart attacks and hospitalizations due to infections in people with type 2 diabetes and obesity. The study found a relative risk reduction of about one-third, corresponding to a 36% reduced risk of infection-related hospitalization.
Researchers found that people with well-controlled HIV have more fibrosis in their fat tissues, leading to insulin resistance and type 2 diabetes. The study also identified a blood marker of scarred fat, which may help predict metabolic future for individuals with HIV.
Researchers tracked nearly 80,000 adults with type 2 diabetes over ten years, finding those who consistently took their prescribed medication stayed free of serious heart and circulatory complications for over seven extra months. Low adherence was linked to a higher risk of cardiovascular disease, especially in younger adults.
A new review suggests that continuous glucose monitoring technology offers no scientific evidence of improved health outcomes in people without diabetes. However, it may be beneficial for those with type 2 diabetes by reducing HbA1c levels and minimizing finger-stick tests.
Adults with type 2 diabetes have a high risk of fragility fractures, but new research found GLP-1 receptor agonists reduce this risk by 21% compared to DPP-4 inhibitors. The largest reductions occurred in hip, femur, and spine fractures.
A new online test, MEDWACS, can detect people with prediabetes or undiagnosed type 2 diabetes with high accuracy. The test measures seven parameters, including thigh length, which is linked to a person's risk of developing the condition.
A study at USC discovers a common genetic variant in Indigenous American populations that silences the microprotein MENTSH, restoring it improves insulin signaling and blocks diet-induced weight gain. MENTSH-based therapies could offer a precision-medicine approach to Type 2 diabetes.
A 16-week personalized exercise intervention improved glycemic regulation, physical fitness and reduced abdominal fat while increasing skeletal muscle mass. Cognitive impairment also showed significant improvements in working memory, perceptual speed and executive function.
A new analysis of 19 randomized controlled trials found that different GLP-1 medications have distinct effects on heart and metabolic health, suggesting a need for personalized treatment selection. Oral GLP-1 therapies are emerging as strong options that could expand accessibility and flexibility.
Researchers have identified transmembrane 4 L six family member 1 (TM4SF1) as a highly selective surface marker of senescent β-cells in both mice and humans. This discovery provides an important step toward developing targeted senotherapies that could preserve insulin secretion and slow the progression of type 2 diabetes.
A new study in the Canadian Journal of Cardiology predicts that generic semaglutide will dramatically increase cost-effectiveness and health system affordability for patients with type 2 diabetes and high cardiorenal risk. The estimated annual cost of providing GLP-1RAs to all indicated patients would be $3.35 to $5.31 billion at pre-g...
Researchers from Rutgers University analyzed US insurance claims data to compare the risk of ischemic optic neuropathy among initiators of GLP-1 RAs versus SGLT-2is or DPP-4is. A small increase in risk was observed, but absolute risk remained very low.
A large Swedish study found that certain bacteria in the gut microbiota can be seen in people who develop type 2 diabetes years later. Fluctuations in metabolism and low fibre intake may also contribute to the risk. The discovery paves the way for early identification of at-risk individuals.
A new study found that GLP-1 receptor agonists can improve long-term health for people with peripheral artery disease (PAD), managing blood sugar and weight loss while reducing inflammation and improving blood vessel function. The benefits were highest among participants with severe PAD and obesity.
Researchers present a roadmap for developing Tregs as adaptable therapies to restore immune balance and support tissue repair. This approach holds promise for treating conditions such as metabolic and cardiovascular disease, as well as neurodegeneration.
New therapies using regulatory T cells, known as Tregs, could target diseases with inflammation, such as cancer and autoimmune conditions. Early evaluations show good tolerance and safety profiles, but precision is key to tailoring treatments for specific patients.
A new study published in Cell Metabolism found that a low-protein, amino acid-supplemented 'longevity diet' improved cardiometabolic markers and reduced frailty and fat mass in mice. The diet was associated with longer healthy lifespan and better metabolic health in both mice and humans.
Researchers at the University of Zurich have developed epigenetic drugs that can reprogram perivascular fat cells to reduce inflammation and improve blood vessel health. By targeting specific gene-expression regulators, these drugs aim to prevent vascular damage in people with obesity and metabolic disease.
A study presented at ENDO 2026 found semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications. The results suggest that semaglutide may have beneficial effects on bone health in people with type 2 diabetes.
A study found that testosterone alone is not enough to prevent type 2 diabetes in older men; lifestyle interventions are crucial for improving blood sugar control and reducing obesity. Testosterone treatment can improve body composition and sexual desire, but its benefits diminish over time.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that enhancing protein-folding processes can help prevent harm to insulin-producing cells. The study revealed the importance of a chaperone protein called binding immunoglobulin protein and its cochaperone protein p58 IPK in maintaining proper proinsulin folding.
A reduction in visceral fat is associated with better cardiometabolic health and lower future type 2 diabetes risk, even when body weight is fully regained. Visceral fat loss achieves a significant protective effect against systemic aging and metabolic decay long after a diet ends.
Researchers at UVA are testing the SIPsmarter program to reduce sugary drink consumption among children and their parents. The study aims to improve beverage quality and overall health outcomes in rural areas with high rates of sugary drink consumption.
Persons with diabetes are at higher risk of periodontitis, tooth loss, and peri-implantitis. Poor blood sugar control exacerbates these risks, highlighting the importance of close collaboration between healthcare and dental care providers.
A study analyzing insurance claims data found similar risks between continued and non-continued GLP-1RA medication use during early pregnancy. The authors conclude that further research is needed to better understand the safety of GLP-1RAs in pregnancy due to imprecise estimates for rare outcomes.
A new study found that U.S. military veterans with both insomnia and obstructive sleep apnea have a substantially elevated risk of developing type 2 diabetes compared to those with either condition alone. The risk is particularly high among younger veterans, even after accounting for demographic and metabolic factors.
A new oral GLP-1 medication, elecoglipron, has been shown to significantly reduce blood glucose levels and bodyweight in adults with type 2 diabetes. The study found that up to 89.6% of participants achieved an HbA1c level of 7%, while 72.3% experienced at least 5% weight reduction.
Researchers found dapagliflozin significantly reduces risk of heart failure hospitalization in individuals carrying a cardiomyopathy genetic variant. The study, published in Nature Medicine, highlights the potential for incorporating genetic screening into heart failure prevention strategies.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
A study found that adding orfglipron to titrated insulin glargine significantly improved glycemic control and body weight in participants with type 2 diabetes. The treatment did not increase the risk of hypoglycemia, compared to placebo.
A major study finds people with diabetes are at higher risk of infection, which can lead to hospitalization and death. The researchers argue that infection prevention and management should be embedded in diabetes guidelines to improve patient outcomes.
Recent studies show finerenone preserves kidney function, reduces cardiovascular risk and improves survival across a broader range of CKD patients. Finerenone also reduces kidney failure, heart failure or cardiovascular death risk by 23-24% in non-diabetic patients.